EMAIL THIS PAGE TO A FRIEND

Gan to kagaku ryoho. Cancer & chemotherapy

[Assessment of host status in patients treated with mFOLFOX6 adjuvant chemotherapy after colorectal cancer surgery].


PMID 24393857

Abstract

We examined the association of the physical, nutritional, and immune status with adverse events in patients treated with mFOLFOX6 adjuvant chemotherapy after colorectal cancer surgery. This study included 17 patients, 7 male and 10 female. The median age was 62( range, 32-75) years. The median number of treatment cycles was 12 (range, 4-12). Age, performance status( PS), body mass index( BMI),serum albumin level( Alb),Onodera's prognostic nutritional index( PNI), controlling nutritional status( CONUT),Glasgow prognostic score( GPS),the granulocyte/lymphocyte ratio( G/L),neutrophil count, and the total lymphocyte count( TLC) were evaluated with regard to the nutrition and immunity status of the host before chemotherapy. The incidents of toxicity of greater than Grade 2 severity, excluding gastrointestinal events or gastrointestinal toxicities, were analyzed to determine the correlation with host status. Any toxicities and toxicities without digestive symptoms were observed in 11 patients( 64.7%),and the number of incidents was significantly increased in patients with a PNI of <45. Gastrointestinal toxicities were observed in 4 patients (23.5%), but there were no significant correlations with any of the factors investigated. Toxicities are observed to a greater extent in patients with a PNI of <45 during adjuvant chemotherapy. These findings suggest that nutritional support may be required to safely administer mFOLFOX6 adjuvant chemotherapy.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

47612
Folinic acid calcium salt hydrate, BioXtra, ≥99.0% (HPLC)
C20H21CaN7O7 · xH2O
F7878
Folinic acid calcium salt hydrate, analytical standard
C20H21CaN7O7 · xH2O